The panel voted to recommend the human papillomavirus (HPV) vaccine be given to boys ages 11 to 12. The vaccine is already recommended for girls of this age.
The rationale behind the recommendation is that the vaccine prevents genital warts and anal cancers in males, both of which can be caused by HPV. The vaccine may also prevent head and neck cancer, which has been on the rise in recent years.
In addition, vaccinating boys may help reduce cervical cancer in women. If males do not acquire the infection, they cannot pass it to females.
The new recommendation "will be a hugely important step in cancer prevention in this country, both for girls and for boys; women as well as men," said Dr. William Schaffner, chairman of the department of preventive medicine at Vanderbilt University, in an interview before the vote. Because rates of HPV vaccination in girls have been low, it's important to vaccinate boys as part of the public health strategy to prevent cervical cancer, Schaffner said.
Although the vaccine has been licensed by the Food and Drug Administration for boys ages 9 to 26, only about 1 percent of males in this age group have received it, said Dr. Paul Offit, chief of the director of the Vaccine Education Center at the Children's Hospital of Philadelphia. After this new recommendation, that percentage should increase dramatically, Offit said.
Boys and men ages 13 to 21 who have not been vaccinated, or haven't received all their shots should also be vaccinated, the committee said.
Benefit for boys and girls
Two of the most common strains of HPV (HPV 16 and 18) cause about 21,000 cancers per year in the United States. One-third of these cancers are in males, according to the CDC.
There are now studies showing the vaccine is effective at preventing genital warts and anal cancers caused by HPV. The recommendation is for the Gardasil vaccine, made by Merck & Co. Inc, which protects against four strains of HPV. The other available HPV vaccine, called Cervarix and made by GlaxoSmithKline, is not licensed for use in males.
And although the vaccine has not been proven to prevent head and neck cancers, which can also be caused by HPV, the recent rise in cases of these cancers likely factored into the panel's reasoning for the recommendation, Schaffner said. Between 1988 and 2004, there was a 28 percent increase in oropharyngeal cancer, a type of head and neck cancer, said Dr. Lauri Markowitz, a member of the CDC committee on HPV vaccines.
In addition, it wasn't previously clear whether vaccinating boys as a means to prevent cervical cancer in girls would be worth the cost. If every girl was vaccinated, the benefit of vaccinating boys would be minimal, and come at a high price, researchers reasoned.
However, new research shows only about 32 percent of U.S. girls receive all three shots of the HPV vaccine (three shots are thought to be optimal for HPV prevention). This low rate of vaccination rate in girls means "it becomes much more sensible to vaccinate the boys also," Schaffner said.
Schaffner also pointed out that the new recommendation will protect men who have sex with men – a group that may not be protected from even a high rate of vaccinations among girls and women.